갑상선 안병증 치료 : 시장 점유율 분석, 업계 동향과 통계, 성장 예측(2026-2031년)

According to Mordor Intelligence, thyroid eye disease treatment market size in 2026 is estimated at USD 5.36 billion, growing from 2025 value of USD 4.94 billion with 2031 projections showing USD 8.09 billion, growing at 8.57% CAGR over 2026-2031.

This report is Segmented by Treatment Modality (Monoclonal Antibody, Small-Molecule Immunosuppressant, and More), Distribution Channel (Hospital Pharmacy, and More), End User (Tertiary-Care Hospitals, and More), and Geography (North America, Europe, Asia-Pacific, The Middle East and Africa, and South America). The Market Forecasts are Provided in Terms of Value (USD).

Global Thyroid Eye Disease Treatment Market Trends and Insights

Rising Global Prevalence of Autoimmune Thyroid Disorders

Thyroid eye disease (TED) accompanies 25-50% of Graves' disease cases and now affects roughly 1 million people in the United States alone. Urban lifestyle stressors, smoking, and iodine intake shifts are intensifying autoimmune thyroid dysfunction rates, especially in high-income economies. Broader recognition of Hashimoto-linked eye involvement enlarges the treatable patient base and reinforces the growth outlook for the thyroid eye disease treatment market. Demographic aging in developed regions further lifts prevalence, aligning with health-system capacity to manage chronic immune-mediated conditions.

Growing Awareness & Screening Programs for Thyroid Dysfunction

Inter-society clinical guidelines between endocrinology and ophthalmology bodies have shortened average time-to-diagnosis from 18-24 months to roughly 6-12 months in specialized centers. Artificial-intelligence decision support embedded in primary care boosts early recognition of orbital changes, and tele-ophthalmology platforms extend specialist reach into rural areas. Earlier detection channels more patients into the active phase when biologic intervention yields maximal visual benefit, reinforcing uptake across the thyroid eye disease treatment market.

High Treatment Costs and Payer Budget-Impact Concerns

An average full-course biologic cost of USD 386,424 per patient, disclosed in company price filings, strains payer budgets. Prior-authorization processes extend beyond thirty days in many US plans, delaying therapy during the critical active disease window. In emerging economies, limited rare-disease budgets force tough resource allocation choices that restrict uptake and temper near-term expansion of the thyroid eye disease treatment market.

Other drivers and restraints analyzed in the detailed report include:

1. Favorable Orphan-Drug Incentives and Reimbursement Pathways
2. Advances in Biologic & Targeted Immunotherapy Platforms
3. Limited Availability of TED-Trained Specialists

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

Monoclonal antibodies captured 67.61% of the thyroid eye disease treatment market share in 2025, underpinned by teprotumumab's 83% proptosis responder rate documented in pivotal trials. Intravenous delivery and hospital-based monitoring supported robust adoption despite logistical complexity. Small-molecule immunosuppressants and orbital radiation retained niche roles for maintenance or refractory cases but collectively accounted for less than one-fifth of revenue.

Pipeline momentum centers on subcutaneous IGF-1R inhibitors and oral agents such as linsitinib, which achieved a 52% proptosis response in Phase 2b/3 testing. Subcutaneous formulations promise at-home administration every 4-8 weeks, a shift likely to redistribute value toward outpatient settings. As these candidates secure approval, they are expected to lift the segment CAGR above the overall market pace, deepening penetration among patients deterred by infusion burdens and reinforcing growth across the thyroid eye disease treatment market.

Complete Report Scope:

• By Treatment Modality
  • Monoclonal Antibody
  • Small-Molecule Immunosuppressant (Mycophenolate, Sirolimus)
  • Corticosteroid (IV, Oral, Local Injection)
  • Orbital Radiation Therapy
  • Other Treatment Modalities
• By Distribution Channel
  • Hospital Pharmacy
  • Specialty/Retail Pharmacy
  • E-commerce & Specialty Distributors
• By End User
  • Tertiary-Care Hospitals
  • Specialty Endocrine/Ophthalmology Clinics
  • Ambulatory Surgery Centers
• Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • Middle East & Africa
    • GCC
    • South Africa
    • Rest of Middle East & Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America maintained a 46.25% revenue share in 2025, reflecting early FDA approval of teprotumumab and widespread insurance coverage. Integrated academic networks supply real-world evidence that steadily increases physician comfort with biologics. The thyroid eye disease treatment market size for North America is projected to reach USD 3.73 billion by 2031, supported by continuous pipeline launches and an aging population.

Europe entered a new growth phase when the European Medicines Agency backed teprotumumab approval in April 2025, initiating country-level pricing negotiations. National health-technology assessments scrutinize cost-effectiveness but tend to green-light therapies that prevent vision loss. Robust research infrastructure facilitates post-marketing surveillance, critical for uptake under outcome-based reimbursement schemes. As local centers emulate US specialty-clinic models, regional penetration should accelerate, especially in Germany, France, and the Nordics.

Asia-Pacific is on track for the fastest regional CAGR of 10.22% through 2031, propelled by rapidly modernizing healthcare systems and increasing endocrinology capacity. Japan already covers teprotumumab under its national insurance, while partnerships such as Amgen-Medii equip clinicians with teleconsultation tools for remote TED management. China and India remain cost-sensitive but are piloting orphan-drug funds that could unlock broader access. Rising autoimmune-disease incidence linked to urban stress and lifestyle change adds further momentum, positioning the thyroid eye disease treatment market for significant scale-up in the region.

1. Amgen
2. Roche
3. Novartis
4. Viridian Therapeutics Inc.
5. Immunovant Inc.
6. Abbvie
7. Pfizer
8. Regeneron Pharmaceuticals
9. Horizon Therapeutics (legacy)
10. Johnson & Johnson
11. Alcon
12. Bausch + Lomb Corp.
13. Santen Pharmaceutical Co. Ltd.
14. Sun Pharmaceuticals Industries
15. Cipla
16. Eyevance Pharmaceuticals
17. Lupin
18. Teva Pharmaceutical Industries
19. Viatris
20. Allakos Inc.

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

TABLE OF CONTENTS

1 Introduction

• 1.1 Study Assumptions & Market Definition
• 1.2 Scope of the Study

2 Research Methodology

3 Executive Summary

4 Market Landscape

• 4.1 Market Overview
• 4.2 Market Drivers
  • 4.2.1 Rising Global Prevalence of Autoimmune Thyroid Disorders
  • 4.2.2 Growing Awareness & Screening Programs for Thyroid Dysfunction
  • 4.2.3 Expansion Of Specialty Ophthalmology & Endocrinology Infrastructure
  • 4.2.4 Favorable Orphan-Drug Incentives and Reimbursement Pathways
  • 4.2.5 Advances In Biologic & Targeted Immunotherapy Platforms
  • 4.2.6 Increasing Healthcare Expenditure on Vision-Saving Therapies
• 4.3 Market Restraints
  • 4.3.1 High Treatment Costs and Payer Budget-Impact Concerns
  • 4.3.2 Limited Availability Of TED-Trained Specialists
  • 4.3.3 Safety & Tolerability Challenges with Systemic Biologics
  • 4.3.4 Regulatory Uncertainty Around Off-Label & Emerging Therapies
• 4.4 Regulatory Landscape
• 4.5 Porter's Five Forces Analysis
  • 4.5.1 Threat of New Entrants
  • 4.5.2 Bargaining Power of Buyers
  • 4.5.3 Bargaining Power of Suppliers
  • 4.5.4 Threat of Substitutes
  • 4.5.5 Intensity of Competitive Rivalry

5 Market Size & Growth Forecasts (Value, USD)

• 5.1 By Treatment Modality
  • 5.1.1 Monoclonal Antibody
  • 5.1.2 Small-Molecule Immunosuppressant (Mycophenolate, Sirolimus)
  • 5.1.3 Corticosteroid (IV, Oral, Local Injection)
  • 5.1.4 Orbital Radiation Therapy
  • 5.1.5 Other Treatment Modalities
• 5.2 By Distribution Channel
  • 5.2.1 Hospital Pharmacy
  • 5.2.2 Specialty/Retail Pharmacy
  • 5.2.3 E-commerce & Specialty Distributors
• 5.3 By End User
  • 5.3.1 Tertiary-Care Hospitals
  • 5.3.2 Specialty Endocrine/Ophthalmology Clinics
  • 5.3.3 Ambulatory Surgery Centers
• 5.4 Geography
  • 5.4.1 North America
    • 5.4.1.1 United States
    • 5.4.1.2 Canada
    • 5.4.1.3 Mexico
  • 5.4.2 Europe
    • 5.4.2.1 Germany
    • 5.4.2.2 United Kingdom
    • 5.4.2.3 France
    • 5.4.2.4 Italy
    • 5.4.2.5 Spain
    • 5.4.2.6 Rest of Europe
  • 5.4.3 Asia-Pacific
    • 5.4.3.1 China
    • 5.4.3.2 Japan
    • 5.4.3.3 India
    • 5.4.3.4 Australia
    • 5.4.3.5 South Korea
    • 5.4.3.6 Rest of Asia-Pacific
  • 5.4.4 Middle East & Africa
    • 5.4.4.1 GCC
    • 5.4.4.2 South Africa
    • 5.4.4.3 Rest of Middle East & Africa
  • 5.4.5 South America
    • 5.4.5.1 Brazil
    • 5.4.5.2 Argentina
    • 5.4.5.3 Rest of South America

6 Competitive Landscape

• 6.1 Market Concentration
• 6.2 Market Share Analysis
• 6.3 Company Profiles (includes Global-level Overview, Market-level Overview, Core Segments, Financials, Strategic Information, Market Rank/Share, Products & Services, Recent Developments)
  • 6.3.1 Amgen Inc.
  • 6.3.2 F. Hoffmann-La Roche Ltd.
  • 6.3.3 Novartis AG
  • 6.3.4 Viridian Therapeutics Inc.
  • 6.3.5 Immunovant Inc.
  • 6.3.6 AbbVie Inc.
  • 6.3.7 Pfizer Inc.
  • 6.3.8 Regeneron Pharmaceuticals Inc.
  • 6.3.9 Horizon Therapeutics (legacy)
  • 6.3.10 Johnson & Johnson Vision Care Inc.
  • 6.3.11 Alcon Inc.
  • 6.3.12 Bausch + Lomb Corp.
  • 6.3.13 Santen Pharmaceutical Co. Ltd.
  • 6.3.14 Sun Pharmaceutical Industries Ltd.
  • 6.3.15 Cipla Ltd.
  • 6.3.16 Eyevance Pharmaceuticals LLC
  • 6.3.17 Lupin Ltd.
  • 6.3.18 Teva Pharmaceutical Industries Ltd.
  • 6.3.19 Viatris Inc.
  • 6.3.20 Allakos Inc.

7 Market Opportunities & Future Outlook

• 7.1 White-space & Unmet-Need Assessment